Flipping the paradigm on malaria transmission-blocking vaccines

Trends in Parasitology

Volumn 24, Issue 8, 2008, Pages 364-370

  Dinglasan, Rhoel R ^a   Jacobs Lorena, Marcelo ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; MALARIA VACCINE; MONOCLONAL ANTIBODY; OUTER SURFACE PROTEIN A; PARASITE ANTIGEN;

ANOPHELES; DRUG RESEARCH; GAMETOCYTE; HUMAN; INFECTION PREVENTION; LIFE CYCLE; MALARIA; MIDGUT; NONHUMAN; OOCYST; PARASITE DEVELOPMENT; PARASITE TRANSMISSION; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM VIVAX; REVIEW; SPOROZOITE; VACCINE PRODUCTION;

ANIMALS; ANOPHELES; ANTIGENS; DISEASE OUTBREAKS; HUMANS; INSECT VECTORS; MALARIA; MALARIA VACCINES;

ANOPHELES (GENUS); INVERTEBRATA;

EID: 47649101526     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2008.05.002     Document Type: Review

References (53)

1. Good M.F. Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol. 21 (2005) 29-34
2. Aponte J.J., et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370 (2007) 1543-1551
3. Tsuboi T., et al. Transmission-blocking vaccine of vivax malaria. Parasitol. Int. 52 (2003) 1-11
4. Vythilingam I., et al. Natural transmission of Plasmodium knowlesi to humans by Anopheles latens in Sarawak, Malaysia. Trans. R. Soc. Trop. Med. Hyg. 100 (2006) 1087-1088
5. Malkin E.M., et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23 (2005) 3131-3138
6. Saul A., et al. Immunogenicity in rhesus of the Plasmodium vivax mosquito stage antigen Pvs25H with Alhydrogel and Montanide ISA 720. Parasite Immunol. 29 (2007) 525-533
7. Hafalla J.C., et al. Minimal variation in the Pfs28 ookinete antigen from Philippine field isolates of Plasmodium falciparum. Mol. Biochem. Parasitol. 87 (1997) 97-99
8. Tsuboi T., et al. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Mol. Med. 4 (1998) 772-782
9. Williamson K.C., and Kaslow D.C. Strain polymorphism of Plasmodium falciparum transmission-blocking target antigen Pfs230. Mol. Biochem. Parasitol. 62 (1993) 125-127
10. Kubler-Kielb J., et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 293-298
11. Kongkasuriyachai D., et al. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy. Vaccine 22 (2004) 3205-3213
12. Coban C., et al. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect. Immun. 72 (2004) 253-259
13. Arevalo-Herrera M., et al. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein. Am. J. Trop. Med. Hyg. 73 (2005) 32-37
14. Arakawa T., et al. Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine 21 (2003) 3143-3148
15. Vincent A.A., et al. Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toxoid. Parasite Immunol. 21 (1999) 573-581
16. Wu Y., et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 18243-18248
17. Qian F., et al. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. Vaccine 25 (2007) 3923-3933
18. Arakawa T., et al. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect. Immun. 73 (2005) 7375-7380
19. Sattabongkot J., et al. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. Am. J. Trop. Med. Hyg. 69 (2003) 536-541
20. Saul A. Mosquito stage, transmission blocking vaccines for malaria. Curr. Opin. Infect. Dis. 20 (2007) 476-481
21. Dinglasan R.R., and Jacobs-Lorena M. Insight into a conserved lifestyle: protein-carbohydrate adhesion strategies of vector-borne pathogens. Infect. Immun. 73 (2005) 7797-7807
22. Pal U., et al. TROSPA, an Ixodes scapularis receptor for Borrelia burgdorferi. Cell 119 (2004) 457-468
23. Kamhawi S., et al. A role for insect galectins in parasite survival. Cell 119 (2004) 329-341
24. Dinglasan R.R., et al. Monoclonal antibody MG96 completely blocks Plasmodium yoelii development in Anopheles stephensi. Infect. Immun. 71 (2003) 6995-7001
25. Dinglasan R.R., et al. Sugar epitopes as potential universal disease transmission blocking targets. Insect Biochem. Mol. Biol. 35 (2005) 1-10
26. Dinglasan R.R., et al. Plasmodium falciparum ookinetes require mosquito midgut chondroitin sulfate proteoglycans for cell invasion. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 15882-15887
27. Zieler H., et al. A tubular network associated with the brush-border surface of the Aedes aegypti midgut: implications for pathogen transmission by mosquitoes. J. Exp. Biol. 203 (2000) 1599-1611
28. Zieler H., et al. Plasmodium gallinaceum ookinetes adhere specifically to the midgut epithelium of Aedes aegypti by interaction with a carbohydrate ligand. J. Exp. Biol. 202 (1999) 485-495
29. Dinglasan R.R., et al. Disruption of Plasmodium falciparum development by antibodies against a conserved mosquito midgut antigen. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 13461-13466
30. Lal A.A., et al. Inhibition of malaria parasite development in mosquitoes by anti-mosquito-midgut antibodies. Infect. Immun. 62 (1994) 316-318
31. Lal A.A., et al. Anti-mosquito midgut antibodies block development of Plasmodium falciparum and Plasmodium vivax in multiple species of Anopheles mosquitoes and reduce vector fecundity and survivorship. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5228-5233
32. Lavazec C., et al. Carboxypeptidases B of Anopheles gambiae as targets for a Plasmodium falciparum transmission-blocking vaccine. Infect. Immun. 75 (2007) 1635-1642
33. Sinden R.E. A proteomic analysis of malaria biology: integration of old literature and new technologies. Int. J. Parasitol. 34 (2004) 1441-1450
34. Ecker A., et al. Plasmodium berghei: plasmodium perforin-like protein 5 is required for mosquito midgut invasion in Anopheles stephensi. Exp. Parasitol. 116 (2007) 504-508
35. Kadota K., et al. Essential role of membrane-attack protein in malarial transmission to mosquito host. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 16310-16315
36. Kariu T., et al. CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. Mol. Microbiol. 59 (2006) 1369-1379
37. Dessens J.T., et al. LCCL proteins of apicomplexan parasites. Trends Parasitol. 20 (2004) 102-108
38. Raine J.D., et al. Female inheritance of malarial lap genes is essential for mosquito transmission. PLoS Pathog. 3 (2007) e30. www.plospathogens.org 10.1371/journal.ppat.0030030
39. Baton L.A., and Ranford-Cartwright L.C. Do malaria ookinete surface proteins P25 and P28 mediate parasite entry into mosquito midgut epithelial cells?. Malar. J. 4 (2005) 15
40. Rodriguez Mdel C., et al. The surface protein Pvs25 of Plasmodium vivax ookinetes interacts with calreticulin on the midgut apical surface of the malaria vector Anopheles albimanus. Mol. Biochem. Parasitol. 153 (2007) 167-177
41. Werz D.B., and Seeberger P.H. Carbohydrates as the next frontier in pharmaceutical research. Chemistry 11 (2005) 3194-3206
42. Pozsgay V. Recent developments in synthetic oligosaccharide-based bacterial vaccines. Curr. Top. Med. Chem. 8 (2008) 126-140
43. Verez-Bencomo V., et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305 (2004) 522-525
44. Pashov A., et al. Targeting carbohydrate antigens in HIV vaccine development. Vaccine 23 (2005) 2168-2175
45. Cipolla L., et al. Glycoconjugates in cancer therapy. Anticancer Agents Med. Chem. 8 (2008) 92-121
46. Dinglasan R.R., et al. Peptide mimics as surrogate immunogens of mosquito midgut carbohydrate malaria transmission blocking targets. Vaccine 23 (2005) 2717-2724
47. Pashov A., et al. Peptide mimotopes as prototypic templates of broad-spectrum surrogates of carbohydrate antigens for cancer vaccination. Crit. Rev. Immunol. 27 (2007) 247-270
48. Foy B.D., et al. Characterization of a unique human single-chain antibody isolated by phage-display selection on membrane-bound mosquito midgut antigens. J. Immunol. Methods 261 (2002) 73-83
49. Labuda M., et al. An antivector vaccine protects against a lethal vector-borne pathogen. PLoS Pathog. 2 (2006) e27. www.plospathogens.org 10.1371/journal.ppat.0020027
50. Kamhawi S., et al. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 290 (2000) 1351-1354
51. Valenzuela J.G., et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J. Exp. Med. 194 (2001) 331-342
52. Donovan M.J., et al. Uninfected mosquito bites confer protection against infection with malaria parasites. Infect. Immun. 75 (2007) 2523-2530
53. Choumet V., et al. The salivary glands and saliva of Anopheles gambiae as an essential step in the Plasmodium life cycle: a global proteomic study. Proteomics 7 (2007) 3384-3394